“Rising Adoption of Disease-Modifying Therapies (DMTs)”
One specific trend contributing to the growth of the amyotrophic lateral sclerosis (ALS) treatment market is the increasing adoption of disease-modifying therapies (DMTs). Recent advancements in drug development, particularly with the approval of therapies such as Relyvrio by Amylyx Pharmaceuticals and Radicava by Mitsubishi Tanabe Pharma, have brought optimism. These treatments aim to slow the disease's progression, offering hope to patients and their families. As a result, more healthcare providers are adopting these therapies to improve the quality of life for ALS patients. The growing pipeline of promising DMTs and their expanding availability are key factors driving market growth.
